Overview

Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
Pfizer
Treatments:
Eletriptan